S were isolated from 30 ml heparinized blood making use of the Ficoll-Paque (Lymphoprep, Axis-Shield), and cryopreserved in liquid nitrogen. The PBMCs had been thawed, washed, and counts and viability had been assessed utilizing the Countess II automated cell counter (Thermo Fisher Scientific). 1 106 cells have been stained within the dark within a 96-well V-bottom plate. The following antibodies have been used for the staining: anti-human CD56 BUV737 (NCAM16.two), CD14 V500 (M5E2), CD19 V500 (HIB19), CCR5 PeCy5 (2D7/CCR5), CD3 AF700 (UCHT1), CD3 BUV805 (UCHT1), Ki-67 BUVPincikova et al. Respiratory Study(2022) 23:Page three ofTable 1 Clinical characteristics of the COPD cohort, according to data collected at inclusion or in the course of follow-upStudy participants Female/Male, n ( ) Age at inclusion, median (variety), years Smoking exposure at inclusion, packyears Existing smoker/Ex-smoker at inclusion, n ( ) Baseline FEV1, predicted Baseline FEV1/FVC, ratio Baseline CAT score Baseline BMI, median (variety) CRP at inclusion (mg/L) Leucocyte count at inclusion (109/L) Heart failure diagnosis at inclusion, Y/N, n ( ) Diabetes mellitus at inclusion, Y/N, n ( ) Frequent exacerbator, Y/N, n ( ) GOLD 2017 group, A/B/C/D, n Death or respiratory insufficiency within three years, Y/N, n ( ) Received antibiotics inside 3 years, Y/N, n ( ) Acute exacerbation(s) inside 3 years, Y/N, n ( ) Total acute exacerbation days inside three years, median (variety) Total hospitalization days inside 3 years, median (variety) Total days on antibiotics per os, median (variety) Total days on intravenous antibiotics, median (range) Baseline CAT 10/CAT 10, n ( ) All (n = 61) 35 (57)/26 (43) 70 (556) 38 (254) 13 (23)/43 (77) 57 (479) 49 (407) 12 (96) 42 (69)/19 (31) 25 (178) 35 (57)/26 (43) three.0 (1.four.two) 7.1 (six.0.four) 15 (25)/46 (75) 11 (18)/50 (82) 10 (16)/51 (84) 18/33/1/9 10 (16)/51 (84) 38 (62)/23 (38) 39 (64)/22 (36) 11 (040) 0 (012) 10 (045) 0 (04) Never hospitalized (n = 40) 24 (60)/16 (40) 70 (555) 40 (255) 7 (20)/28 (80) 62 (500) 50 (417) 11 (86) 26 (65)/14 (35) 25 (188) 18 (45)/22 (55) two.9 (1.three.7) six.6 (five.8.2) 7 (17.5)/33 (82.5) 5 (12.5)/35 (87.5) 2 (5)/38 (95) 14/24/0/2 1 (2.five)/39 (97.5) 18 (45)/22 (55) 21 (52.5)/19 (47.5) 6 (09) 0 (0) 0 (05) 0 (0) Hospitalized (n = 21) 11 (52)/10 (48) 69 (566) 37 (230) six (29)/15 (71) 51 (403) 44 (367) 14 (107) 16 (76)/5 (24) 26 (175) 17 (81)/4 (19) 3.7 (1.7.9) 7.five (6.7.6) eight (38)/13 (62) six (29)/15 (71) eight (38)/13 (62) 4/9/1/7 9 (43)/12 (57) 20 (95)/1 (5) 18 (86)/3 (14) 20 (040) 9 (112) 35 (045) 3 (04) p-value 0.597 0.701 0.324 0.523 0.039 0.307 0.074 0.561 0.703 0.Serum Albumin/ALB Protein MedChemExpress 013 0.HGF Protein Purity & Documentation 074 0.PMID:24856309 019 0.117 0.164 0.002 0.0001 0.0001 0.012 0.004 0.00000 0.00001 0.Inhaled corticosteroids at inclusion, Y/N, n ( )Values are medians with interquartile ranges, unless stated otherwise. Percentages are of those with valid information For comparison of groups Mann hitney U Test was employed, for comparing proportions, Fisher’s Precise Test was employed Heart failure was defined in accordance with the patient records; diagnosed by the clinical image and/or heart echocardiography Frequent exacerbator was defined as a patient with 2 or extra acute exacerbations per year throughout the 3 years of follow-up (counted as total number of acute exacerbations through the three follow-up years divided by three years) Respiratory insufficiency was defined as onset of require of long-term oxygen treatment or will need of long-term non-invasive ventilation Acute exacerbation was defined as an episode of acutely or sub-acutely worsened dyspnea BMI body mass index, CAT chronic ob.